IDH1 and malignant glioma: In the literature on recurrent malignant glioma, there are reports that IDH mutation was associated with a better prognosis [39], whereas there are also reports of better results with IDH wildtype malignant glioma with respect to combined stereotactic radiotherapy with bevacizumab [4].